sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Thrombosis and Hemostasis Biomarkers Market Size study, by Product Type by Application, by End-user and Regional Forecasts 2024-2032

Global Thrombosis and Hemostasis Biomarkers Market Size study, by Product...

Home / Categories / Healthcare
Global Thrombosis and Hemostasis Biomarkers Market Size study, by Product Type by Application, by End-user and Regional Forecasts 2024-2032
Global Thrombosis and Hemostasis Biomarkers...
Report Code
RO1/103/3047

Publish Date
13/Sep/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Global Thrombosis and Hemostasis Biomarkers Market is valued at approximately USD 5.31 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.9% over the forecast period 2024-2032. Thrombosis and hemostasis biomarkers are laboratory parameters derived from the components of the hemostatic system, such as von Willebrand factor (vWF), fibrinogen, D-dimer, and others. These biomarkers are instrumental in detecting certain diseases or their pathophysiological effects and have numerous applications in clinical practice. They offer significant benefits, including the risk estimation and diagnosis of venous thromboembolism (VTE) and other conditions, prediction of thrombotic events in patients with lymphoma, response to chemotherapy in patients with pancreatic cancer, and enhanced patient management.

The growth of the thrombosis and hemostasis biomarkers market is highly attributed to the increased risk of venous thromboembolism (VTE). The risk of VTE is associated with various clinical conditions such as cardiovascular, cerebrovascular, and malignant disorders. In addition, the risk increases with major or minor injuries and obesity. For instance, according to the American Heart Association, Inc. in November 2023, obese individuals have an increased risk of VTE, and the higher the risk becomes as the weight increases. Biomarkers such as D-dimer, fibrinogen, and factor VIII are used to predict the risk of VTE and monitor treatment response. This is expected to significantly boost the adoption of biomarker products, propelling the market growth during the forecast timeframe. Moreover, the growing research initiatives and funding and increasing adoption of biomarkers in clinical practice present various lucrative opportunities over the forecast years. However, the high cost and stringent regulations as well as limitations associated with biomarker use are challenging the market growth throughout the forecast period of 2024-2032.

The key regions considered for the Global Thrombosis and Hemostasis Biomarkers Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global Thrombosis and Hemostasis Biomarkers Market in terms of revenue. The market growth in the area is being attributed to factors including the presence of a highly developed healthcare infrastructure, significant investments in research and development, and the widespread adoption of advanced diagnostic technologies. The United States leads the market due to a high prevalence of cardiovascular diseases and blood disorders, as well as strong collaborations between academic institutions and industry players to develop innovative diagnostic solutions. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising healthcare expenditures, increasing prevalence of thrombotic disorders, and a growing awareness of the importance of early diagnosis and treatment. Countries such as China, India, and Japan are experiencing significant market expansion due to the increasing burden of lifestyle-related diseases, expanding middle-class populations with improved access to healthcare, and government initiatives aimed at enhancing healthcare quality and accessibility.

Major market player included in this report are:
F. Hoffmann-La Roche Ltd
BioMedica Diagnostics
Siemens Healthcare Private Limited
Abbott
HORIBA Medical
BIOMERIEUX
QuidelOrtho Corporation
Stago Group
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Beckman Coulter, Inc.
Sysmex Corporation
Enzo Biochem, Inc.
Diazyme Laboratories, Inc.
Agilent Technologies, Inc.
The detailed segments and sub-segment of the market are explained below:
By Product Type:
Instruments
Reagents & Consumables
By Application:
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Disseminated Intravascular Coagulation (DIC)
Others
By End-user:
Hospitals & Clinics
Diagnostic Laboratories
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com